乳腺癌患者基质金属蛋白酶抑制因子-1和人类表皮生长因子受体-2表达的临床意义研究
|
摘要
目的观察基质金属蛋白酶抑制因子-1(TIMP-1)和人类表皮生长因子受体-2(HER-2)在乳腺癌患者中的表达及其临床意义。方法收集2007年1月至2008年12月收治的乳腺癌患者98例,所有病例均随访5年,分析TIMP-1和HER-2在乳腺癌中的表达与不同临床病理特征的关系,应用总生存时间(OS)评估患者预后情况。结果全组肿瘤组织TIMP-1阳性表达率为57.14%,HER-2为42.86%,二者的表达与患者年龄、肿瘤大小、临床分期和病理类型均无关(P>0.05);TIMP-1的表达与淋巴结转移、组织学分级有关(P<0.05);HER-2与雌激素受体(ER)、孕激素受体(PR)状态有关(P<0.05)。TIMP-1表达者5年生存率为61.79%,低于TIMP-1未表达者的66.64%,差异无统计学意义(P>0.05);HER-2表达者5年生存率为56.43%明显低于未表达者的64.32%(P<0.05)。结论 TIMP-1表达者可能与肿瘤淋巴转移、组织分化有关,但不能作为不良预后的独立指标;HER-2阳性表达者5年生存率明显较低,可作为不良预后指标。
Objective To investigate the clinical significance of tissue inhibitors of metalloproteinase-1( TIMP-1) and human epidermal growth factor receptor 2( HER-2) expression in breast cancer patients.Methods 98 breast cancer patients from January 2006 to December 2007 were collected and followed-up for 5 years,then the relations between TIMP-1,HER-2 and clinical pathological features of breast cancer patients were analyzed,and the overall survival( OS) was applied to assess the patients' prognosis.Results The rate of TIMP-1 positive expression was 57.14%,and HER-2 was 42.86%.The TMP-1 and HER-2 expressions and patient age,tumor size,clinical stage and histological type were irrelevant( P > 0.05);TIMP-1 expression and lymph node metastasis,histological grade were relevant( P < 0.05);HER-2 and ER,PR status information were relevant( P < 0.05),the 5-year survival rate of patients with TIMP-1 expression( 61.79%) was less than that of patients with no TIMP-1 expression( 66.64%),and there was no statistical difference( P > 0.05);the 5-year survival rate of patients HER-2 expression( 56.43%) was significantly lower than that of patients with the negative HER-2 expression( 64.32%),and there was statistical difference( P < 0.05).Conclusion TIMP-1 expression is related to lymphatic metastasis and tissue differentiation but it may be not an independent predictor of poor prognosis.The 5-year survival rate of HER-2 positive expression is significantly lower,which could be used as an adverse prognostic indicator.
Objective To investigate the clinical significance of tissue inhibitors of metalloproteinase-1( TIMP-1) and human epidermal growth factor receptor 2( HER-2) expression in breast cancer patients.Methods 98 breast cancer patients from January 2006 to December 2007 were collected and followed-up for 5 years,then the relations between TIMP-1,HER-2 and clinical pathological features of breast cancer patients were analyzed,and the overall survival( OS) was applied to assess the patients' prognosis.Results The rate of TIMP-1 positive expression was 57.14%,and HER-2 was 42.86%.The TMP-1 and HER-2 expressions and patient age,tumor size,clinical stage and histological type were irrelevant( P > 0.05);TIMP-1 expression and lymph node metastasis,histological grade were relevant( P < 0.05);HER-2 and ER,PR status information were relevant( P < 0.05),the 5-year survival rate of patients with TIMP-1 expression( 61.79%) was less than that of patients with no TIMP-1 expression( 66.64%),and there was no statistical difference( P > 0.05);the 5-year survival rate of patients HER-2 expression( 56.43%) was significantly lower than that of patients with the negative HER-2 expression( 64.32%),and there was statistical difference( P < 0.05).Conclusion TIMP-1 expression is related to lymphatic metastasis and tissue differentiation but it may be not an independent predictor of poor prognosis.The 5-year survival rate of HER-2 positive expression is significantly lower,which could be used as an adverse prognostic indicator.
引文
[1]樊嵘,金冶宁.TIMP-1在乳腺癌中的作用机制和临床意义[J].现代肿瘤医学,2009,17(1):154-156.
[2]Wurtz S,Schrohl AS,Moundsen H.TIMP-1 as a tumor marker in breast cancer-an update[J].Acta Oncol,2008(47):580-590.
[3]郭通,庞达.Ki SS-1、TIMP-1在乳腺癌中的表达及在淋巴结转移中的意义[J].齐齐哈尔医学院学报,2010,31(7):1 012-1 014.
[4]Daniele A,Lito AF,Giannelli G,et al.Expression of metal-loproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer[J].Anticancer Res,2010,30(9):3 521-3 528.
[5]刘君,杨艳芳,傅西林,等.基质金属蛋白酶抑制因子1和nm-23在人表皮生长因子受体2阳性乳腺癌中的表达及意义[J].中华肿瘤杂志,2012,34(8):600-602.
[6]张绍坤,郭冰,王雷,等.金属蛋白酶组织抑制因子员在乳腺癌组织中的表达及其与多种生物学指标的关系[J].中华乳腺病杂志(电子版),2011,5(5):542-544.
[7]韩晓红,石远凯,马丽,等.应用FISH和IHC技术检测中国乳腺癌患者HER-2基因状态及蛋白表达的前瞻性多中心研究[J].中华检验医学杂志,2010,33(7):655-657.
[8]杨黎,朱霞,冉立.HER-2、PCNA、Bcl-2、Bax在乳腺癌组织中的表达与预后的关系[J].癌症,2007,26(7):756-761.
[9]王言,姚璐,刘毅,等.人表皮生长因子受体2表达对腋淋巴结阳性和阴性乳腺癌患者预后的不同影响[J].中华肿瘤杂志,2010,2(7):511-513.
[10]张青,李小欢,杨真,等.110例乳腺癌患者HER-2基因扩增状况及其与临床病理特征的关系[J].中国医药导报,2013,10(11):86-88.
[11]杨丽丽,梁莉萍,赵峰.ER、PR、HER-2、Ki67、Nm23、P53在多中心性乳腺癌中的表达及临床意义[J].重庆医科大学学报,2012,37(11):964-966.
[12]王鸿雁,张学斌,蒋伊娜,等.乳腺癌HER-2基因扩增的临床病理意义[J].肿瘤防治研究,2010,37(11):1 264-1 268.
[13]李春艳,张晟,刘艳,等.三阴型乳腺癌159例临床病理特征分析[J].实用癌症杂志,2012,27(6):624-626.
[2]Wurtz S,Schrohl AS,Moundsen H.TIMP-1 as a tumor marker in breast cancer-an update[J].Acta Oncol,2008(47):580-590.
[3]郭通,庞达.Ki SS-1、TIMP-1在乳腺癌中的表达及在淋巴结转移中的意义[J].齐齐哈尔医学院学报,2010,31(7):1 012-1 014.
[4]Daniele A,Lito AF,Giannelli G,et al.Expression of metal-loproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer[J].Anticancer Res,2010,30(9):3 521-3 528.
[5]刘君,杨艳芳,傅西林,等.基质金属蛋白酶抑制因子1和nm-23在人表皮生长因子受体2阳性乳腺癌中的表达及意义[J].中华肿瘤杂志,2012,34(8):600-602.
[6]张绍坤,郭冰,王雷,等.金属蛋白酶组织抑制因子员在乳腺癌组织中的表达及其与多种生物学指标的关系[J].中华乳腺病杂志(电子版),2011,5(5):542-544.
[7]韩晓红,石远凯,马丽,等.应用FISH和IHC技术检测中国乳腺癌患者HER-2基因状态及蛋白表达的前瞻性多中心研究[J].中华检验医学杂志,2010,33(7):655-657.
[8]杨黎,朱霞,冉立.HER-2、PCNA、Bcl-2、Bax在乳腺癌组织中的表达与预后的关系[J].癌症,2007,26(7):756-761.
[9]王言,姚璐,刘毅,等.人表皮生长因子受体2表达对腋淋巴结阳性和阴性乳腺癌患者预后的不同影响[J].中华肿瘤杂志,2010,2(7):511-513.
[10]张青,李小欢,杨真,等.110例乳腺癌患者HER-2基因扩增状况及其与临床病理特征的关系[J].中国医药导报,2013,10(11):86-88.
[11]杨丽丽,梁莉萍,赵峰.ER、PR、HER-2、Ki67、Nm23、P53在多中心性乳腺癌中的表达及临床意义[J].重庆医科大学学报,2012,37(11):964-966.
[12]王鸿雁,张学斌,蒋伊娜,等.乳腺癌HER-2基因扩增的临床病理意义[J].肿瘤防治研究,2010,37(11):1 264-1 268.
[13]李春艳,张晟,刘艳,等.三阴型乳腺癌159例临床病理特征分析[J].实用癌症杂志,2012,27(6):624-626.